Search results
Found 6785 matches for
Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.
Oxford Medicine December 2020
Oxford Medicine December 2020
Oxford Medicine Spring Summer 2021
Oxford Medicine Spring Summer 2021
Oxford Medicine Summer 2022
Oxford Medicine Summer 2022
Oxford Medicine Magazine - Winter 2023
Oxford Medicine Magazine - Winter 2023
Oxford Medicine Autumn Winter 2021
Oxford Medicine Autumn Winter 2021